Founded in Hamburg, Germany in 1945, Eppendorf AG has more than 3,300 employees worldwide and has subsidiaries in 26 countries and is represented in all important markets by distributors. In an interaction with BioSpectrum India, Eva van Pelt, Co-Chief Executive Officer & Chief Commercial Officer, Eppendorf AG, who was appointed to this position on December 6, 2019 shared her view about the company’s contributions in the fight against COVID-19 and the growth plans of the company. Edited excerpts;
What have been your key contributions within the organization towards fighting COVID-19?
The current challenges posed by the corona virus are both a mission and a motivation for us. Since the company’s beginnings more than 75 years ago, Eppendorf has pursued the mission of “improving human living conditions”. The importance of this mission, yesterday and today, is also evident in the current situation concerning the coronavirus. As part of this mission we focus on two main aspects – the safety and health of our global workforce and providing laboratories with the best and reliable equipment.
All employees, who are able to do so, to work from home. This measure in return not only protects them and their families but also all colleagues who cannot work from home, such as in production and logistics. Furthermore, amongst other aspects, wearing personal protection equipment is mandatory as well as complying with the needed social distance.
Protecting our employees also contributes to the second aspect – serving our customers on the frontline of the battle against the coronavirus. Here our primary goal is to ensure Eppendorf’s production and delivery capacity. Our customers can count on us to deliver and support their tireless effort of developing vaccines and medications.
How have you been able to tackle the pressure created by the pandemic?
Continue reading your story on the app
Continue reading your story in the magazine
Rare diseases policy outlines challenges sans solutions
There is no substantial data on the number of people suffering from rare diseases in India and the data that is available is from tertiary care hospitals. The lack of epidemiological data on rare diseases makes it a herculean task to determine the prevalence and burden of rare diseases, hence hampering the definition of rare diseases in the Indian context.
PSA launches community mental-health digital platform
The Principal Scientific Adviser (PSA) to the Government of India Prof. K VijayRaghavan has virtually launched ‘MANAS’ App to promote wellbeing across age groups.
“India should have a vibrant clinical research community who can advise drug developers”
The Indian Society for Clinical Research (ISCR), an association of clinical research professionals, has announced the appointment of Dr Sanish Davis as its President for the term 202123.
MALARIA DENGUE TB PLAY SECOND FIDDLE to COVID - 19
Although India has worked relentlessly towards developing innovative testing solutions for COVID-19 throughout last year, the timely detection of a number of other infectious diseases has been sidelined. In India, the range and burden of infectious diseases such as tuberculosis, malaria, filariasis, leprosy, HIV infection, typhoid, hepatitis etc., are enormous. In fact, inadequate containment of the vector has resulted in recurrent outbreaks of dengue fever and re-emergence of chikungunya virus disease and typhus fever. If India can develop more than 20 different diagnostic tests or devices in a single year to fight COVID-19, many more such innovations can be brought to effectively detect other infections looming in our country.
Govt fast-tracks emergency approvals for foreign-made COVID-19 vaccines
The matter of augmenting the basket of vaccines available for fighting the pandemic as well as accelerating the pace and coverage of domestic vaccination programmes was discussed recently at the 23rd meeting of the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC).
Wipro Focuses On Transforming Vaccine Safety Assessment
Bengaluru -based IT firm Wipro has announced a partnership with Hyderabad-based Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI).
Dr. Reddy's Launches Sputnik V Vaccine In India
Dr. Reddy’s Laboratories announced that the first consignment of imported doses of the Sputnik V vaccine that landed in India on May 1, 2021, received regulatory clearance from the Central Drugs Laboratory, Kasauli, on May 13, 2021. As part of a limited pilot, the soft launch of the vaccine has commenced and the first dose of the vaccine was administered in Hyderabad on May 14, 2021.
“Made in India products need an ecosystem for commercialisation of innovations”
Established in 1998, Ernakulam-based Agappe Diagnostics is one of the rapidly growing companies in the in vitro diagnostic (IVD) industry in India, having a wide range of products in the pre-analytical and analytical segment. Focused on research, design, and production of clinical chemistry reagents and instrument, Agappe has over 1000 distributors and holds a significant place in the global original equipment manufacturer (OEM) business. The company currently has a workforce of more than 600 employees spread across sectors such as R&D, manufacturing, sales, support and operations. In conversation with BioSpectrum, Thomas John, Managing Director, Agappe Diagnostics, Ernakulam shares his strategies and plans for the company’s growth in the long run.
Vocalising pain is a must
Women have unique health issues. In fact, some of the health issues that affect both men and women can affect women very differently.
“India should focus on innovating drugs and molecules to emerge as a global leader”
The Organisation of Pharmaceutical Producers of India (OPPI) has elected S Sridhar as its next President for a period of two years, effective from February 15, 2021. He takes over from Sharad Tyagi, Former Managing Director, Boehringer Ingelheim India Pvt Ltd. Sridhar is currently serving as the Managing Director of Pfizer Limited and is heading Pfizer Inc’s commercial business in India. Sridhar has been a member of the Executive Committee of OPPI for the past six years and has also chaired its Finance and Taxation Work Group. He is a strong voice of healthcare transformation in the country and was the chair of FICCI’s Pharma Committee till recently. In conversation with BioSpectrum, S Sridhar talks about making a difference to patients, the industry and the country via this new role.
Be Happy & Fulfilled
Simple Steps To Change Your Life!
Cuba Bets Big on Its Own Vaccines
If they prove effective, locally made drugs could be an economic lifeline for the island
VIRUS TESTING STRATEGIES, OPINIONS VARY WIDELY IN US SCHOOLS
Children are having their noses swabbed or saliva sampled at school to test for the coronavirus in cities such as Baltimore, New York and Chicago. In other parts of the U.S., school districts are reluctant to check even students showing signs of illness for COVID-19.
COVID hold lifted, hoping for games soon
Morey playing for Bucksport
Your Post-Covid Health Plan
Recovering from COVID-19 and it’s taking a while? Or you’ve avoided the virus but feel anxious about returning to normal? Here’s everything you need to know to keep safe and healthy
Ourlads' Giants draft analysis
A year full of firsts due to the COVID-19 pandemic made the entire process leading up to the 2021 NFL Draft both unorthodox and limited.
A Vaccine for all Occasions
Scientists are developing a “universal vaccine” that would protect against anything the coronavirus can throw at us and maybe even the common cold.
The Winter of Discontent
Even though america is preparing for a summer reopening, the Coronavirus will still be around to dog us when the temperatures fall.
She had seen him through some difficult times. Could he help see her through the pandemic?
Covid Means There's Even Less Joy in Mudville
Capacity constraints and distancing rules bring big headaches for season ticket holders